Knopp Biosciences Announces Publication of Eosinophil-lowering Effects of Dexpramipexole in Multiple Clinical Trials

Knopp Biosciences LLC announced the publication of results from multiple clinical trials demonstrating the eosinophil-lowering effects of dexpramipexole, a small molecule treatment in development for eosinophil-associated diseases. “The totality of the evidence to date, across multiple clinical studies in multiple … Continued

Panopto Announces Record-Breaking Growth in 2016

Panopto, a leading provider of enterprise video platform for businesses and universities, today announced that 2016 was its strongest year yet. Panopto achieved record business growth in 2016, with worldwide enterprise bookings growing 52 percent year over year. Customer commitment to … Continued

Xpress Natural Gas Fueling Station Announces 88 New Jobs

Pennsylvania Governor, Tom Wolf, announced Xpress Natural Gas will build a natural gas fueling station in Susquehanna County. Xpress Natural Gas, LLC is a pioneer of the “virtual pipeline” that provides a network of compression stations and lightweight, high-capacity trailers. … Continued

Knopp Biosciences Receives Key Patent Directed to Treatment for Hypereosinophilic Syndromes, Asthma, and Other Eosinophilic Diseases

Knopp Biosciences LLC announced it received U.S. Patent No. 9,468,630 entitled “Compositions and Methods for Treating Conditions Related to Increased Eosinophils”.  The patent relates to the company’s clinical-stage small molecule dexpramipexole, which Knopp expects to advance into pivotal trials in … Continued

Knopp Biosciences Reported Steroid-sparing Effects of Dexpramipexole in HES at American Society of Hematology 2016 Annual Meeting

Knopp Biosciences LLC today announced the presentation of data from an ongoing, open-label pilot-study of dexpramipexole in hypereosinophilic syndromes (HES) demonstrating hematological responses, symptom improvement, and steroid sparing in a subset of subjects with steroid-dependent HES. Full results from the … Continued